BMO Capital Markets Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by equities researchers at BMO Capital Markets from $800.00 to $600.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 22.99% from the stock’s previous close.

A number of other equities research analysts have also weighed in on REGN. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a research report on Monday. Bernstein Bank reduced their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $700.00 to $580.00 in a research report on Friday, May 30th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $847.40.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $487.86 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals has a 52 week low of $481.58 and a 52 week high of $1,211.20. The stock has a market capitalization of $52.67 billion, a P/E ratio of 12.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The stock has a fifty day moving average of $578.30 and a 200-day moving average of $662.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in REGN. Capital International Investors raised its stake in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $802,036,000. GAMMA Investing LLC raised its stake in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Finally, Nuveen LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $343,764,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.